Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ECTRIMS 2019
Pharma
Roche's Ocrevus, given early, cuts wheelchair risk by 42%: study
Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.
Carly Helfand
Sep 13, 2019 11:52am
Novartis' reinvented leukemia drug bests Sanofi's Aubagio in MS
Sep 13, 2019 11:18am
Merck KGaA touts Mavenclad data as MS new drug race heats up
Sep 13, 2019 11:08am
Novartis' Mayzent delays wheelchair use by 4 years: analysis
Sep 12, 2019 12:26pm
Biogen's Tecfidera is safe, effective after 10-plus years: study
Sep 11, 2019 5:00am
Roche's Ocrevus combats biomarker that may spur MS progression
Sep 10, 2019 11:45am
